|
1
|
Langhans TH: Ueber einen Drüsenpolyp im
ileum. Virchows Arch Euro J Pathol. 38:pp559–560. 1867. View Article : Google Scholar
|
|
2
|
Oberndorfer S: Karzinoide tumoren des
dunndarms. Frankf Z Pathol. 1:426–432. 1907.
|
|
3
|
Modlin IM, Shapiro MD, Kidd M and Eick G:
Siegfried Oberndorfer and the evolution of carcinoid disease. Arch
Surg. 142:187–197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Modlin IM, Oberg K, Chung DC, Jensen RT,
de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA,
Krenning EP, et al: Gastroenteropancreatic neuroendocrine tumours.
Lancet Oncol. 9:61–72. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Klimstra DS, Modlin IR, Adsay NV, Chetty
R, Deshpande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, et
al: Pathology reporting of neuroendocrine tumors: Application of
the Delphic consensus process to the development of a minimum
pathology data set. Am J Surg Pathol. 34:300–313. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Japanese society for cancer of the colon
and rectum: General rules for clinical and pathological studies on
cancer of the colon, rectum and anus. 8th edn. Tokyo: Japanese
society for cancer of the colon and rectum; 2013
|
|
7
|
Yegutkin GG: Nucleotide- and nucleoside
converting ectoenzymes: Important modulators of purinergic
signalling cascade. Biochim Biophys Acta. 1783:673–694. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jin D, Fan J, Wang L, Thompson LF, Liu A,
Daniel BJ, Shin T, Curiel TJ and Zhang B: CD73 on tumor cells
impairs antitumor T-cell responses: A novel mechanism of
tumor-induced immune suppression. Cancer Res. 70:2245–2255. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Beavis PA, Divisekera U, Paget C, Chow MT,
John LB, Devaud C, Dwyer K, Stagg J, Smyth MJ and Darcy PK:
Blockade of A2A receptors potently suppresses the metastasis of
CD73+ tumors. Proc Natl Acad Sci USA. 110:14711–14716. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stagg J, Divisekera U, McLaughlin N,
Sharkey J, Pommey S, Denoyer D, Dwyer KM and Smyth MJ: Anti-CD73
antibody therapy inhibits breast tumor growth and metastasis. Proc
Natl Acad Sci USA. 107:1547–1552. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ohta A, Gorelik E, Prasad SJ, Ronchese F,
Lukashev D, Wong MK, Huang X, Caldwell S, Liu K, Smith P, et al:
A2A adenosine receptor protects tumors from antitumor T cells. Proc
Natl Acad Sci USA. 103:13132–13137. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stagg J, Divisekera U, Duret H, Sparwasser
T, Teng MW, Darcy PK and Smyth MJ: CD73-deficient mice have
increased antitumor immunity and are resistant to experimental
metastasis. Cancer Res. 71:2892–2900. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang L, Fan J, Thompson LF, Zhang Y, Shin
T, Curiel TJ and Zhang B: CD73 has distinct roles in
nonhematopoietic and hematopoietic cells to promote tumor growth in
mice. J Clin Invest. 121:2371–2382. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Katsuta E, Tanaka S, Mogushi K, Shimada S,
Akiyama Y, Aihara A, Matsumura S, Mitsunori Y, Ban D, Ochiai T, et
al: CD73 as a therapeutic target for pancreatic neuroendocrine
tumor stem cells. Int J Oncol. 48:657–669. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Beavis PA, Slaney CY, Milenkovski N,
Henderson MA, Loi S, Stagg J, Kershaw MH and Darcy PK: CD73: A
potential biomarker for anti-PD-1 therapy. Oncoimmunology.
4:e10466752015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rindi G, Arnold R and Bosman FT:
Nomenclature and classification of neuroendocrine neoplasms of the
digestive systemWHO Classification of Tumors of the Digestive
System. IARC; Lyon: pp. 13–14. 2010
|
|
17
|
Oh HK, Sin JI, Choi J, Park SH, Lee TS and
Choi YS: Overexpression of CD73 in epithelial ovarian carcinoma is
associated with better prognosis, lower stage, better
differentiation and lower regulatory T cell infiltration. J Gynecol
Oncol. 23:174–281. 2012. View Article : Google Scholar
|
|
18
|
Ito T, Igarashi H, Nakamura K, Sasano H,
Okusaka T, Takano K, Komoto I, Tanaka M, Imamura M, Jensen RT, et
al: Epidemiological trends of pancreatic and gastrointestinal
neuroendocrine tumors in Japan: A nationwide survey analysis. J
Gastroenterol. 50:58–64. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mocellin S and Nitti D: Gastrointestinal
carcinoid: Epidemiological and survival evidence from a large
population-based study (n=25 531). Ann Oncol. 24:3040–3044. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yao JC, Hassan M, Phan A, Dagohoy C, Leary
C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A and Evans
DB: One hundred years after ‘carcinoid’: Epidemiology of and
prognostic factors for neuroendocrine tumors in 35,825 cases in the
United States. J Clin Oncol. 26:3063–3072. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pavel M, Baudin E, Couvelard A, Krenning
E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B and Salazar R:
Barcelona Consensus Conference participants: ENETS consensus
guidelines for the management of patients with liver and other
distant metastases from neuroendocrine neoplasms of foregut,
midgut, hindgut, and unknown primary. Neuroendocrinology.
95:157–176. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oberg K: Diagnosis and treatment of
carcinoid tumors. Expert Rev Anticancer Ther. 3:863–877. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ikeda K, Kojima M, Saito N, Sakuyama N,
Koushi K, Watanabe T, Sugihara K, Akimoto T, Ito M and Ochiai A:
Current status of the histopathological assessment, diagnosis, and
reporting of colorectal neuroendocrine tumors: A web survey from
the Japanese society for cancer of colon and rectum. Pathol Int.
66:94–101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bosman FT, Carneiro F, Hruban RH and
Theise ND: WHO classification of tumors of the digestive system,
4th edition. Lyon. Int Agency Res Cancer. 3:pp4172010.
|
|
25
|
Soga J: The term ‘carcinoid’ is a
misnomer: The evidence based on local invasion. J Exp Clin Cancer
Res. 28:152009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Parkins CS, Darling JL, Gill SS, Revesz T
and Thomas DG: Cell proliferation in serial biopsies through human
malignant brain tumours: Measurement using Ki67 antibody labelling.
Br J Neurosurg. 5:289–298. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Torp SH and Alsaker M: Ki-67
immunoreactivity, basic fibroblastic growth factor (bFGF)
expression, and microvessel density as supplementary prognostic
tools in low-grade astrocytomas. An immunohistochemical study with
special reference to the reliability of different Ki-67 antibodies.
Pathol Res Pract. 198:261–265. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Voss SM, Riley MP, Lokhandwala PM, Wang M
and Yang Z: Mitotic count by phosphohistone H3 immunohistochemical
staining predicts survival and improves interobserver
reproducibility in well-differentiated neuroendocrine tumors of the
pancreas. Am J Surg Pathol. 39:13–24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Reid MD, Balci S, Saka B and Adsay NV:
Neuroendocrine tumors of the pancreas: Current concepts and
controversies. Endocr Pathol. 25:65–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cross SS, Start RD and Smith JH: Does
delay in fixation affect the number of mitotic figures in processed
tissue? J Clin Pathol. 43:597–599. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Inoue Y, Yoshimura K, Kurabe N, Kahyo T,
Kawase A, Tanahashi M, Ogawa H, Inui N, Funai K, Shinmura K, et al:
Prognostic impact of CD73 and A2A adenosine receptor expression in
non-small-cell lung cancer. Oncotarget. 8:8738–8751.
2017.PubMed/NCBI
|
|
32
|
Wu XR, He XS, Chen YF, Yuan RX, Zeng Y,
Lian L, Zou YF, Lan N, Wu XJ and Lan P: High expression of CD73 as
a poor prognostic biomarker in human colorectal cancer. J Surg
Oncol. 106:130–137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lu XX, Chen YT, Feng B, Mao XB, Yu B and
Chu XY: Expression and clinical significance of CD73 and
hypoxia-inducible factor-1α in gastric carcinoma. World J
Gastroenterol. 19:1912–1918. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xiong L, Wen Y, Miao X and Yang Z: NT5E
and FcGBP as key regulators of TGF-1-induced epithelial-mesenchymal
transition (EMT) are associated with tumor progression and survival
of patients with gallbladder cancer. Cell Tissue Res. 355:365–374.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Turcotte M, Spring K, Pommey S, Chouinard
G, Cousineau I, George J, Chen GM, Gendoo DM, Haibe-Kains B, Karn
T, et al: CD73 is associated with poor prognosis in high-grade
serous ovarian cancer. Cancer Res. 75:4494–4503. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Loi S, Pommey S, Haibe-Kains B, Beavis PA,
Darcy PK, Smyth MJ and Stagg J: CD73 promotes anthracycline
resistance and poor prognosis in triple negative breast cancer.
Proc Natl Acad Sci USA. 110:11091–11096. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Arozarena I, Sanchez-Laorden B, Packer L,
Hidalgo-Carcedo C, Hayward R, Viros A, Sahai E and Marais R:
Oncogenic BRAF induces melanoma cell invasion by downregulating the
cGMP-specific phosphodiesterase PDE5A. Cancer Cell. 19:45–57. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Aliagas E, Vidal A, Texidó L, Ponce J,
Condom E and Martín-Satué M: High expression of ecto-nucleotidases
CD39 and CD73 in human endometrial tumors. Mediators Inflamm.
2014:5090272014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kojima M, Ikeda K, Saito N, Sakuyama N,
Koushi K, Kawano S, Watanabe T, Sugihara K, Ito M and Ochiai A:
Neuroendocrine tumors of the large intestine: Clinicopathological
features and predictive factors of lymph node metastasis. Front
Oncol. 6:1732016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Allard B, Pommey S, Smyth MJ and Stagg J:
Targeting CD73 enhances the antitumor activity of anti-PD-1 and
anti-CTLA-4 mAbs. Clin Cancer Res. 19:5626–5635. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Balar AV and Weber JS: PD-1 and PD-L1
antibodies in cancer: Current status and future directions. Cancer
Immunol Immunother. 66:551–564. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Phillips T, Simmons P, Inzunza HD,
Cogswell J, Novotny J Jr, Taylor C and Zhang X: Development of an
automated PD-L1 immunohistochemistry (IHC) assay for non-small cell
lung cancer. Appl Immunohistochem Mol Morphol. 23:541–549. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rangachari D, VanderLaan PA, Shea M, Le X,
Huberman MS, Kobayashi SS and Costa DB: Correlation between classic
driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50%
expression in lung adenocarcinoma. J Thorac Oncol. 12:878–883.
2017. View Article : Google Scholar : PubMed/NCBI
|
